Avalo Therapeutics, Inc. (AVTX) earnings
AVTX earnings moved a median of -1.78% by the close. Quarterly and annual AVTX reports and results, each read against the price at its own news timestamp. Back to the AVTX overview →
22 measured AVTX earnings events.
Where these AVTX earnings landedvs 22 measured AVTX earnings reactions
| Middle 50% of AVTX earnings reactions | -3.61% to +1.50% |
|---|---|
| Median reaction (to close) | -1.78% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 AVTX earnings events with a measured close landed between -3.61% and +1.50%; 36% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates | Press release | +4.39% | +4.64% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +4.39% | +4.64% | |
| Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates | Press release | -1.86% | -1.78% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | -1.86% | -1.78% | |
| Form 10-K Avalo Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | +1.19% | +0.60% | |
| Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates | Press release | +3.98% | -2.53% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +3.98% | -2.53% | |
| Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates | Press release | +0.00% | +0.00% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +0.00% | |
| Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates | Press release | +1.21% | -3.61% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +1.21% | -3.61% | |
| Form 10-K Avalo Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | — | +3.01% | |
| Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates | Press release | +0.00% | +3.94% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +3.94% | |
| Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates | Press release | -1.68% | -7.48% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Jun 30 | SEC filing · Form 10-Q | -1.68% | -7.48% | |
| Form 10-Q/A Avalo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -2.80% | |
| Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates | Press release | +0.82% | +1.50% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.82% | +1.50% | |
| Form 10-K Avalo Therapeutics, Inc. For: Dec 31 | SEC filing · Form 10-K | -6.95% | -10.50% | |
| Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates | Press release | +0.94% | -8.41% | |
| Form 10-Q Avalo Therapeutics, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.94% | -8.41% |
Keep exploring
More AVTX: analyst actions → · SEC filings → · AVTX overview →